Outset Medical (NASDAQ:OM – Get Free Report) will be issuing its quarterly earnings data after the market closes on Wednesday, August 7th. Analysts expect the company to announce earnings of ($0.43) per share for the quarter. Outset Medical has set its FY 2024 guidance at EPS.Parties that wish to register for the company’s conference call can do so using this link.
Outset Medical (NASDAQ:OM – Get Free Report) last announced its quarterly earnings data on Wednesday, May 8th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.13). Outset Medical had a negative net margin of 134.93% and a negative return on equity of 120.67%. The business had revenue of $28.17 million during the quarter, compared to the consensus estimate of $30.55 million. On average, analysts expect Outset Medical to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Outset Medical Stock Down 4.4 %
Shares of NASDAQ OM opened at $3.51 on Wednesday. Outset Medical has a one year low of $1.92 and a one year high of $20.75. The company has a debt-to-equity ratio of 2.11, a current ratio of 6.42 and a quick ratio of 5.32. The business’s fifty day moving average price is $3.97 and its 200-day moving average price is $3.30. The stock has a market capitalization of $181.54 million, a PE ratio of -1.04 and a beta of 2.00.
Insider Buying and Selling
Wall Street Analysts Forecast Growth
A number of brokerages have recently commented on OM. CL King raised Outset Medical from a “neutral” rating to a “buy” rating and set a $6.00 price target on the stock in a research report on Friday, April 5th. BTIG Research began coverage on Outset Medical in a research report on Monday, April 8th. They set a “buy” rating and a $6.00 price target on the stock. Finally, Royal Bank of Canada raised Outset Medical from a “sector perform” rating to an “outperform” rating and upped their price target for the company from $5.00 to $6.00 in a research report on Friday, June 21st. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, Outset Medical presently has a consensus rating of “Moderate Buy” and an average target price of $5.42.
Read Our Latest Stock Report on Outset Medical
About Outset Medical
Outset Medical, Inc, a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables.
Featured Stories
- Five stocks we like better than Outset Medical
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Invest Like Congress: 2 ETFs to Add to Your Watchlist
- How to Calculate Return on Investment (ROI)
- AI Boom or Bubble? Strategies for Success in a Volatile Sector
- What is a Special Dividend?
- Oilfield Infrastructure Stock Soars Over 50% on Bold Acquisition
Receive News & Ratings for Outset Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Outset Medical and related companies with MarketBeat.com's FREE daily email newsletter.